Insights into gait disorders: Walking variability using phase plot analysis, Huntington's disease

Gait and Posture

Volumn 40, Issue 4, 2014, Pages 694-700

  Collett, Johnny ^a   Esser, Patrick ^a   Khalil, Hanan ^b   Busse, Monica ^c   Quinn, Lori ^c   DeBono, Katy ^c   Rosser, Anne ^c   Nemeth, Andrea H ^d   Dawes, Helen ^a,c,d  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Gait; Huntington's disease; Motor control; Outcome measure; Variability

Indexed keywords

ACCELERATION; ADULT; ANALYTIC METHOD; ARTICLE; CAG REPEAT; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; GAIT; GAIT DISORDER; HEART RATE VARIABILITY; HUMAN; HUNTINGTON CHOREA; INVOLUNTARY MOVEMENT; LEG LENGTH; LUMBAR VERTEBRA; MALE; MIDDLE AGED; MOTOR PERFORMANCE; NEUROLOGIC DISEASE ASSESSMENT; OBSERVATIONAL STUDY; PHASE PLOT ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPATIOTEMPORAL ANALYSIS; TOTAL MOTOR SCORE; UNIFIED HUNTINGTON DISEASE RATING SCALE; VOLUNTARY MOVEMENT; WALKING SPEED; NEUROLOGIC GAIT DISORDER; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; WALKING DIFFICULTY;

FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOBILITY LIMITATION; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84921964466     PISSN: 09666362     EISSN: 18792219     Source Type: Journal    
DOI: 10.1016/j.gaitpost.2014.08.001     Document Type: Article

References (25)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
2. Tabrizi S.J., Reilmann R., Roos R.A., Durr A., Leavitt B., Owen G., et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2014, 11:42-53.
3. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2014, 10:83-98.
4. Esser P., Dawes H., Collett J., Howells K. IMU: Inertial sensing of vertical CoM movement. J Biomech 2009, 42:1578-1581.
5. Meichtry A., Romkes J., Gobelet C., Brunner R., Muller R. Criterion validity of 3D trunk accelerations to assess external work and power in able-bodied gait. Gait Posture 2007, 25:25-32.
6. Rao A.K., Muratori L., Louis E.D., Moskowitz C.B., Marder K.S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 2008, 23:1100-1107.
7. Delval A., Bleuse S., Simonin C., Delliaux M., Rolland B., Destee A., et al. Are gait initiation parameters early markers of Huntington's disease in pre-manifest mutation carriers. Gait Posture 2014, 34:202-207.
8. Rao A.K., Mazzoni P., Wasserman P., Marder K. Longitudinal change in gait and motor function in pre-manifest Huntington's disease. PLoS Curr 2011, 3:RRN1268.
9. Zijlstra W., Hof A.L. Assessment of spatio-temporal gait parameters from trunk accelerations during human walking. Gait Posture 2003, 18:1-10.
10. Esser P., Dawes H., Collett J., Howells K. Insights into gait disorders: walking variability using phase plot analysis, Parkinson's disease. Gait Posture 2013, 38(4):648-652.
11. Bechtel N., Scahill R.I., Rosas H.D., Acharya T., van den Bogaard S.J., Jauffret C., et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurol 2014, 75:2150-2160.
12. Shoulson I., Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
13. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997, 41:689-692.
14. Esser P., Dawes H., Collett J., Howells K. IMU: inertial sensing of vertical CoM movement. J Biomech 2009, 42:1578-1581.
15. Esser P., Dawes H., Collett J., Feltham M.G., Howells K. Assessment of spatio-temporal gait parameters using inertial measurement units in neurological populations. Gait Posture 2014, 34:558-560.
16. Batterham A.M., George K.P. Reliability in evidence-based clinical practice: a primer for allied health professionals. Phys Ther Sport 2003, 4:122-128.
17. Verlindena V.J.A., van der Geest J.N., Hofman A., Ikrama M.A. Cognition and gait show a distinct pattern of association in the general population. Alzheimers Dement 2014, 10(3):328-335.
18. Hausdorff J.M., Cudkowicz M.E., Firtion R., Wei J.Y., Goldberger A.L. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 1998, 13:428-437.
19. Hausdorff J.M. Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos 2009, 19(2):026113.
20. Antoniades C.A., Ober J., Hicks S., Siuda G., Carpenter R.H., Kennard C., et al. Statistical characteristics of finger-tapping data in Huntington's disease. Med Biol Eng Comput 2014, 50:341-346.
21. Sano H., Yasoshima Y., Matsushita N., Kaneko T., Kohno K., Pastan I., et al. Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function. J Neurosci 2003, 23:9078-9088.
22. Paulsen J.S., Hayden M., Stout J.C., Langbehn D.R., Aylward E., Ross C.A., et al. Preparing for preventive clinical trials: the predict-HD study. Arch Neurol 2006, 63:883-890.
23. Rosano C., Brach J., Studenski S., Longstreth W.T., Newman A.B. Gait variability is associated with subclinical brain vascular abnormalities in high-functioning older adults. Neuroepidemiology 2007, 29:193-200.
24. Plotnik M., Giladi N., Hausdorff J.M. A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease. Exp Brain Res 2007, 181:561-570.
25. Weir D.W., Sturrock A., Leavitt B.R. Development of biomarkers for Huntington's disease. Lancet Neurol 2011, 10:573-590.